Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Portfolio
  • Forum
  • Discovery
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

Simris Group

0.08 SEK

-10.00 %

Less than 1K followers

SIMRIS B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
-10.00 %
-14.74 %
+89.25 %
+89.25 %
-34.68 %
-27.35 %
-83.64 %
-86.05 %
-98.54 %

Simris Group is a biotechnology company. The company is focused on research and development of bioactive substances from cultured microalgae, for applications in nutrition, cosmeceuticals and pharmaceuticals. The company's technology also replaces unsustainable raw materials from endangered species and sensitive marine ecosystems. Simris Group was founded in 2011 and is headquartered in Hammenhög.

Read more
Market cap
109.33M SEK
Turnover
19.3K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
13.5.
2026

Interim report Q1'26

27.5.
2026

General meeting '26

12.8.
2026

Interim report Q2'26

All
Press releases
3rd party
ShowingAll content types
Press release3/19/2026, 1:00 PM

Simris evaluating options to expand its ADC-payload development programme and prepare for the next funding round to accelerate its plans.

Simris Group
Press release3/11/2026, 10:20 AM

Simis provides an update on the divestment of its assets in Hammenhög, Sweden

Simris Group
Regulatory press release2/28/2026, 7:00 AM

SIMRIS GROUP YEAR-END REPORT JANUARY-DECEMBER 2025

Simris Group

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release1/19/2026, 3:30 PM

Bulletin from Simris Group AB’s extraordinary general meeting

Simris Group
Press release1/19/2026, 1:00 PM

Simris Group enters into Memorandum of Understanding regarding divestment of assets in Hammenhög

Simris Group
Regulatory press release12/16/2025, 8:32 PM

Simris Group AB (publ) receives notice of conversion of convertible bonds

Simris Group
Regulatory press release12/16/2025, 7:45 PM

Notice of extraordinary general meeting in Simris Group AB (publ)

Simris Group
Regulatory press release12/16/2025, 7:43 PM

Simris Group AB resolves on directed issue of units, proposes that an extraordinary general meeting resolves on additional share issues and announces acceptance of premature conversion of convertible debentures

Simris Group
Regulatory press release11/28/2025, 3:51 PM

Simris Group enters into bridge loan agreement

Simris Group
Regulatory press release11/12/2025, 7:00 AM

SIMRIS GROUP INTERIM REPORT JANUARY-SEPTEMBER 2025

Simris Group
Regulatory press release11/10/2025, 7:30 AM

Simris Group announces leadership transition - Daniel Kubitza appointed interim CEO

Simris Group
Regulatory press release11/5/2025, 12:00 PM

Simris Group AB Announces Positive Results from Ongoing Antibody-Drug Conjugate (ADC) Study with Nuvisan

Simris Group
Regulatory press release10/6/2025, 7:30 AM

Update Regarding In-Vitro Evaluation of Novel Advance Microcystin Payloads

Simris Group
Press release9/12/2025, 8:00 AM

Simris Biologics awarded €200K in non-dilutive funding for R&D programme to further develop microcystin payloads for Antibody Drug Conjugates (ADCs)

Simris Group
Regulatory press release8/13/2025, 6:00 AM

SIMRIS GROUP INTERIM REPORT JANUARY-JUNE 2025

Simris Group
Regulatory press release7/27/2025, 7:57 PM

Simris Group AB (publ) resolves on a directed issue of convertible debentures of EUR 678,000 and amends existing loan facilities

Simris Group
Regulatory press release7/12/2025, 4:38 AM

Partner Company Decides Not to Proceed with Simris Group ADC Proposed Collaboration Following Strategic Review

Simris Group
Press release6/5/2025, 7:15 AM

Simris Biologics Signs Agreement with Nuvisan for In-Vivo Evaluation of Novel Microcystin Payloads

Simris Group
Regulatory press release6/2/2025, 6:55 AM

Simris Group AB Signs Non-Binding Concept Sheet for Potential Antibody-Drug Conjugate Collaboration

Simris Group
Regulatory press release5/28/2025, 3:10 PM

Bulletin from Simris Group AB’s annual general meeting

Simris Group
Forum discussions
Want more examples? During my 25-30 year investing career, especially regarding IPOs (and even more so crowdfunding), I’ve noticed that a company that doesn’t communicate is usually a bad investment. Fortunately, I’ve only had a few grand in these, max €5k. Medicortex and Fifax are...
5/10/2023, 8:37 PM
by Eskimo68
3
Another share issue underway; they are planning (again) to list on First North. Interesting, I can’t even find information on whether the previous issue was successful and if more funding was secured from Business Finland. Maybe it was mentioned at the AGM, but I wasn’t particularly...
8/6/2024, 1:13 PM
by Eskimo68
1
Since information is so sparse, I’ll continue writing critically. Reluctantly, because scaring off potential new investors doesn’t exactly help my own stake. The fact that there is a new quick “offering” (well described, @Hysky) is worrying. If the management is competent, raising...
1/10/2023, 2:46 PM
by Eskimo68
1
I attended the 2026 annual general meeting. Nothing particularly noteworthy, essentially, they’re awaiting Nosium’s Reverse TakeOver. I expressed a dissenting opinion on the board’s “giant compensation packages,” especially considering the company’s continuous positive results . ...
3/31/2026, 11:38 AM
by Eskimo68
0
They have another share issue underway right now at a price of €1, so in that sense, the share value is theoretically increasing. Once again, information is far too scarce. If there were at least some kind of shareholder list available so we knew who has invested in the company, ...
1/24/2024, 5:16 PM
by Eskimo68
0
They managed to raise 110k€ by the end of May. That’s presumably a fairly good amount already. Now, if I only had the energy to dig into how much the company spends each month, which is of course difficult because part of it probably comes from the DoD’s pot. Then when you add “new...
6/8/2023, 5:08 PM
by Eskimo68
0
Let me add that if minority shareholders owned 20-30% of the company based on these n+1 share issues, the company would already be on a sounder footing. I couldn’t find the current ownership structure myself (though I have requested it in the past). On a sound footing, it could then...
5/10/2023, 8:41 PM
by Eskimo68
0
Read more on our forum
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.